deep brain stimulation
The FDA offered Medtronic a broader approval for its deep brain stimulator to treat Parkinson's disease. The expansion will put it roughly on par with a PMA approval for St. Jude Medical's Brio that came last June.
GlaxoSmithKline has been quietly working on bioelectronic medicines for years--after having established an R&D unit dedicated to it in 2012, which was followed by a $50 million venture fund in 2013, and then a $5 million innovation challenge in 2014. Although it hasn't disclosed much about the fruits of its efforts, it has done a new deal to add to them.
Functional Neuromodulation, a startup backed by Medtronic and the National Institutes of Health, will advance its deep brain stimulation implant into a Phase III trial to treat Alzheimer's disease patients. DBS is a standard treatment for movement disorders, such as Parkinson's disease, but hasn't been widely applied to other brain disorders.
Researchers nabbed a $6.8 million, 5-year grant from the National Institutes of Health to develop technology to predict, track and treat epileptic seizures. The grant is part of the ongoing BRAIN (Brain Research Through Advancing Innovative Neurotechnologies) Initiative launched by President Obama.
St. Jude Medical has received a CE mark for its latest neuromodulation technology--the Infinity Deep Brain Stimulation System to treat movement disorders. It expects to get sign-off from the FDA and to launch the system in the U.S. before year's end. The franchise is the latest addition to St. Jude's neuromodulation business, which last quarter grew faster than the company's other groups in cardiac rhythm management, atrial fibrillation and cardiovascular.
Medtronic has published detailed results for the first time of a 5-year trial for deep brain stimulation therapy in treatment-resistant epilepsy. The device giant has said that it will make another run at an FDA approval for its DBS device in that indication.
The market for deep brain stimulation to treat Parkinson's is heating up. Boston Scientific said its Vercise device is performed well in clinical trials.
Medtronic has developed a first-of-its-kind implant, pairing traditional deep-brain stimulation with sensing technology, and, after performing its first procedure, the company says the device has a chance to change the standard of care for neurological disorders.
A deep brain stimulation implant used in a small pilot study helped some patients with severe anorexia gain weight and boosted their mood.
Two Medtronic deep brain stimulation device-implants, in combination with drugs, helped improve symptoms in patients with early-stage Parkinson's disease, according to a new study.